ARCHIVES

Rituximab Prolonged Survival Of CLL In Phase III Study

This article is from The Cancer Letter archive.

Vol. 33 No. 9 | September 24, 2010

Download PDF Visit The Full Archive

Related Articles

ODAC Votes 13:0 For Approving Perjeta

September 27, 2013

Alimta Reduces Risk Of Progression In Patients Aged 70 Years or Older

October 28, 2011

AACR, NCCR Advocate Five-Year Plan to Reach $10 billion Annual Cancer Budget

April 30, 1999

Adjuvant BC Therapy Is Topic Of NIH Consensus Conference.

January 28, 2000

In Brief: Sundwall Leaves Hatch to head HRSA; Terry Joins Damon Biotech; Irlin On Hunger Strike

September 12, 1986

As MD Anderson Targets Eight Cancers, Detailed War Plan Remains Under Wraps

September 21, 2012